文献速递鼻科小儿耳鼻咽喉

白三烯受体拮抗剂联合鼻内激素治疗变应性鼻炎的系统评价与荟萃分析

Leukotriene receptor antagonist addition to intranasal steroid: systematic review and meta-analysis.
PubMed 文献 · Rhinology · 2021-01-01

该系统评价与荟萃分析纳入6项随机对照试验共358例变应性鼻炎患者,比较鼻内皮质激素联合白三烯受体拮抗剂与单用鼻内皮质激素的疗效。结果显示联合治疗在鼻部症状、疾病特异性生活质量及不良事件方面与单药治疗无差异,但在眼部症状改善上可能更优。

要点

  • 联合治疗与单用鼻内皮质激素在鼻部症状评分上无差异
  • 联合治疗在疾病特异性生活质量和不良事件方面与单药无差异
  • 联合治疗可能更有利于改善眼部症状

核心结论

  • 鼻内皮质激素联合白三烯受体拮抗剂在改善鼻部症状和生活质量方面与单用鼻内皮质激素无差异,但可能更优改善眼部症状。

研究设计与样本

  • 系统评价与荟萃分析,纳入比较鼻内皮质激素联合白三烯受体拮抗剂与单用鼻内皮质激素治疗变应性鼻炎的随机对照试验,共6项研究358例参与者。

主要发现

  • 联合治疗与单药治疗在复合鼻症状评分、日间总症状评分、夜间总症状评分、疾病特异性生活质量及不良事件方面均无差异。
  • 结果支持联合治疗对眼部症状的改善效果。

临床怎么用

  • 对于变应性鼻炎患者,联合白三烯受体拮抗剂并未显示优于单用鼻内皮质激素的鼻部症状控制,但眼部症状突出者可考虑联合治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intranasal corticosteroids (INCS) and leukotriene receptor antagonist (LTRA) have different mechanisms of action. The combination of INCS and LTRA (INCS+LTRA) are utilized to control the allergic rhinitis (AR) symptoms. The effects of this com- bination have not been made evident yet. METHODOLOGY: Randomized controlled trials studying the effects of INCS+LTRA vs INCS in monotherapy on rhinoconjunctivitis symptoms in patients with AR were included. Data were pooled for meta-analysis. The outcomes were nasal symptoms, ocular symptoms, disease-specific quality of life (QOL), and adverse events. RESULTS: Six studies (358 participants) met the inclusion criteria. There were no differences between INCS+LTRA and INCS mono- therapy on composite nasal symptom score, total daytime symptom score, total night time symptom score, disease-specific QOL and adverse events. The results favoured the effects of INCS-LTRA on ocular symptoms. CONCLUSIONS: The effects of the INCS+LTRA combination are not different from INCS in monotherapy in the improvement of both nasal symptoms and patient's QOL. The combination may, however, be better on improving ocular symptoms.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. Seresirikachorn K, Mullol J, Limitlaohaphan K, et al. Leukotriene receptor antagonist addition to intranasal steroid: systematic review and meta-analysis. Rhinology. 2021. PMID: 32692787. doi:10.4193/Rhin20.126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。